-
Product Insights
NewThromboembolism – Drugs In Development, 2024
Empower your strategies with our Thromboembolism – Drugs In Development, 2024 report and make more profitable business decisions. A thromboembolism occurs when a blood clot (thrombus) break and travels in the bloodstream. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy, and surgery. The Thromboembolism drugs in development market research report provide comprehensive information...
-
Product Insights
NewThrombosis – Drugs In Development, 2024
Empower your strategies with our Thrombosis – Drugs In Development, 2024 report and make more profitable business decisions. Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. This clot can obstruct the normal blood flow, potentially leading to various health complications. Thrombosis can occur in both veins and arteries. Common types include Deep Vein Thrombosis (DVT), where clots form in deep veins, often in the legs, and Pulmonary Embolism (PE), which occurs when a...
-
Product Insights
NewIschemic Stroke – Drugs In Development, 2024
Empower your strategies with our Ischemic Stroke – Drugs In Development, 2024 report and make more profitable business decisions. Ischemic stroke occurs when there is a disruption of blood flow to a part of the brain, leading to a lack of oxygen and nutrients. This can happen when a blood vessel that supplies blood to the brain becomes blocked or narrowed, often due to the formation of a blood clot or plaque buildup within the vessel. The blockage can occur within...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Ovarian Cancer Drug Details: IPI-549 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Varoglutamstat in Mild Cognitive Impairment
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Varoglutamstat in Mild Cognitive ImpairmentDrug Details:PQ-912 is under development for the treatment of early stage mild...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NRL-1049 in Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NRL-1049 in Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NRL-1049 in Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous...
-
Sector Analysis
Atrial Fibrillation Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032
Atrial Fibrillation Market Report Overview The AF market size across the 8MM was valued at $14.53 billion in 2022 and will decline at a CAGR of more than 1% during 2022-2032. However, the launch of a total of 5 products, including four anticoagulants and one cardioversion agent each of which will have a higher annual cost of therapy (ACOT) when compared with the cost of generic NOACs and the commonly used pharmacological agents respectively will drive market growth during the...
-
Sector Analysis
Venous Thromboembolism Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032
Venous Thromboembolism Market Report Overview Venous thromboembolism market size across the 7MM was valued at $3.57 billion in 2022 and will achieve a CAGR of more than 2% during 2022-2032. The market growth can be attributed to the large size of the VTE patient population in the US as well as the higher overall price of drugs as compared to the 5EU and Japan. Venous Thromboembolism Market Outlook, 2022-2032 ($ Billion) Buy Full Report to Get More Insights into the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – abelacimab
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry abelacimab Drug Details Abelacimab is under development for the prevention of arterial and venous...